Oncology Business Management

Latest News


Latest Videos


CME Content


More News

The FDA granted the selective tropomyosin receptor kinase inhibitor LOXO-101 a breakthrough therapy designation for the treatment of adult or pediatric patients with unresectable or metastatic solid tumors with NTRK-infusion proteins who progressed on prior therapy or have no other available treatment options.

The Centers for Medicare & Medicaid Services is wavering on its commitment to the Medicare reform package passed in 2015, based on widespread concerns that the changes may be unwieldy and could increase the pace at which smaller physician practices are being forced into mergers.

Many oncology practices were motivated to join the Oncology Care Model in order to keep up with the evolution of value-based care. But when the Center for Medicare & Medicaid Innovation started telling practices that their applications had been accepted, it was panic time for some.

A year after announcing its intention to launch the Oncology Care Model alternative payment plan for oncology care, The Centers for Medicare & Medicaid Services said it has 196 practices enrolled across the United States and that the official start date is Friday, July 1.